<DOC>
	<DOCNO>NCT01270750</DOCNO>
	<brief_summary>Vasoconstrictive signal via endothelin receptor limit primary pulmonary arterial hypertension , also document secondary pulmonary hypertension due congestive heart failure , include cardiac valve disease . The investigator aim examine clinical physiologic effect bosentan therapy patient secondary pulmonary hypertension due severe , inoperable cardiac valve disease , use single-center , prospective , open-label , non-randomized study oral bosentan outpatient severe mitral stenosis due childhood rheumatoid fever . Primary end-point exercise capacity six month determine six-minute walk distance cardiopulmonary exercise testing . Secondary end-points symptomatic relief , echocardiographic leave ventricular function pulmonary pressure , serum pro-brain natriuretic peptide , adverse event six month .</brief_summary>
	<brief_title>Bosentan Severe Mitral Valve Dysfunction</brief_title>
	<detailed_description />
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Heart Failure</mesh_term>
	<mesh_term>Neoplasm Metastasis</mesh_term>
	<mesh_term>Hypertension , Pulmonary</mesh_term>
	<mesh_term>Mitral Valve Stenosis</mesh_term>
	<mesh_term>Endothelin Receptor Antagonists</mesh_term>
	<mesh_term>Bosentan</mesh_term>
	<criteria>Outpatient &gt; 60 Yrs Old &lt; 85 Yrs Old Stable disease Congestive heart failure NYHA IIIB/V Inoperable mitral stenosis due childhood rheumatoid fever Mean pulmonary artery pressure &gt; 40 cm H2O Prior treatment endothelin receptor antagonist ( ) Hospitalization ( exacerbation ) Cardiac valve surgery</criteria>
	<gender>All</gender>
	<minimum_age>60 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>January 2011</verification_date>
	<keyword>ENDOTHELIN RECEPTOR ANTAGONIST</keyword>
	<keyword>BOSENTAN</keyword>
	<keyword>SECONDARY PULMONARY HYPERTENSION</keyword>
	<keyword>RHEUMATOID FEVER</keyword>
	<keyword>CONGESTIVE HEART FAILURE</keyword>
	<keyword>SECONDARY PULMONARY HYPERTENSION DUE TO MITRAL STENOSIS</keyword>
</DOC>